Literature DB >> 29569119

More efficacious, equally safe: a meta-analysis comparing the safety of direct oral anticoagulants versus aspirin.

Jeffrey Y Bien1, Derrick L Tao2, Molly M Daughety3, Thomas G DeLoughery3, Joseph J Shatzel3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29569119     DOI： 10.1007/s11239-018-1648-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  7 in total

Review 1.  The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis.

Authors:  Chatree Chai-Adisaksopha; Mark Crowther; Tetsuya Isayama; Wendy Lim
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

2.  Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Authors:  Jeffrey I Weitz; Anthonie W A Lensing; Martin H Prins; Rupert Bauersachs; Jan Beyer-Westendorf; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Bruce L Davidson; Hervé Decousus; Maria C S Freitas; Gerlind Holberg; Ajay K Kakkar; Lloyd Haskell; Bonno van Bellen; Akos F Pap; Scott D Berkowitz; Peter Verhamme; Philip S Wells; Paolo Prandoni
Journal:  N Engl J Med       Date:  2017-03-18       Impact factor: 91.245

3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

4.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

5.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Authors:  Jonathan Mant; F D Richard Hobbs; Kate Fletcher; Andrea Roalfe; David Fitzmaurice; Gregory Y H Lip; Ellen Murray
Journal:  Lancet       Date:  2007-08-11       Impact factor: 79.321

7.  Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke.

Authors:  Jonathan C Hsu; Thomas M Maddox; Kevin Kennedy; David F Katz; Lucas N Marzec; Steven A Lubitz; Anil K Gehi; Mintu P Turakhia; Gregory M Marcus
Journal:  J Am Coll Cardiol       Date:  2016-06-28       Impact factor: 24.094
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.